The endothelin system and its role in pulmonary arterial hypertension (PAH)

Pepke-Zaba, J.; Morrell, N. W.
June 2005
Thorax;Jun2005, Vol. 60 Issue 6, p443
Academic Journal
Endothelin receptor antagonists represent a major advance in the treatment of PAH but much remains to be learned of their effectiveness in specific forms of pulmonary hypertension


Related Articles

  • Sitaxsentan more effective than bosentan as PAH therapy.  // Formulary;Jan2006, Vol. 41 Issue 1, p46 

    The article examines the effectiveness of sitaxsentan compared with bosentan for the treatment of pulmonary arterial hypertension (PAH). Sitaxsentan is a highly selective endothelin-A receptor antagonist. It may be beneficial for patients with PAH due to connective tissue disease. It is also...

  • Endothelin: 20 years from discovery to therapy. Barton, Matthias; Yanagisawa, Masashi // Canadian Journal of Physiology & Pharmacology;Aug2008, Vol. 86 Issue 8, p485 

    Since its identification as an endothelial cell-derived vasoconstrictor peptide in 1988, endothelin-1, the predominant member of the endothelin peptide family, has received considerable interest in basic medical science and in clinical medicine, which is reflected by more than 20 000 scientific...

  • Interactions of Prostacyclin and Endothelin. Clapp, Lucie // Current Medical Literature: Pulmonary Hypertension;2012 Supplement, p2 

    The article explores the health benefits of a combination of endothelin receptor antagonists (ERAs) and prostacyclin therapy. It mentions a study conducted by the author and colleagues which tries to culture pulmonary smooth muscle cells from idiopathic pulmonary arterial hypertension (PAH)...

  • Comparative Safety and Tolerability of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension. Aversa, Meghan; Porter, Sandra; Granton, John // Drug Safety;May2015, Vol. 38 Issue 5, p419 

    Pulmonary arterial hypertension (PAH) is a condition that leads to progressive right heart failure and death unless recognized and treated early. Endothelin, a potent endogenous vasoconstrictor, has been identified as an important mediator of PAH. Endothelin receptor antagonists (ERAs) have been...

  • Increased Plasma Endothelin--1 Pulmonary Hypertension: Marker or Mediator of Disease? Stewart, Duncan J.; Levy, Robert D.; Cernacek, Peter; Langleben, David // Annals of Internal Medicine;3/15/91, Vol. 114 Issue 6, p464 

    Explores the role of endothelin-1, a potent endothelial-derived vasoconstrictor peptide, in pulmonary hypertension. Design of the study; Results; Conclusions.

  • ERRATUM.  // Advances in Pulmonary Hypertension;2014, Vol. 13 Issue 3, p158 

    A correction to the section "Ask the Expert" in the Volume 13, No. 2, issue of the journal is presented.

  • Macitentan approved for pulmonary arterial hypertension.  // WHO Drug Information;2013, Vol. 27 Issue 4, p357 

    The article discusses the U.S. Food and Administration's (FDA) approval of macitentan (Opsumit), an endothelin receptor blocker and adult treatment for pulmonary arterial hypertension (PAH).

  • Sitaxentan: worldwide withdrawal.  // WHO Drug Information;2010, Vol. 24 Issue 4, p307 

    The article reports on a 2010 decision which the Therapeutic Goods Administration of Australia made to announce that the supply of the prescription medicine sitaxentan will be suspended because the company that supplies the medicine announced that it will withdraw the drug from the global market.

  • The endothelin system in pulmonary hypertension. Michel, Rene P.; Langleben, David; Dupuis, Jocelyn // Canadian Journal of Physiology & Pharmacology;Jun2003, Vol. 81 Issue 6, p542 

    Pulmonary hypertension (PH) may result from numerous clinical entities affecting the pulmonary circulation primarily or secondarily. It is recognized that vascular endothelial dysfunction contributes to the development and perpetuation of PH by creating an imbalance between vasodilating and...


Read the Article


Sign out of this library

Other Topics